An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Abstract

Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.).

Keywords

Affiliated Institutions

• University of Miami US
• University of Minnesota US
• University of Iowa US
• Yale University US
• University of South Florida US
• Indiana University – Purdue University Indianapolis US
• University of Florida US
• University of Toronto CA
• Children's Mercy Hospital US
• Vanderbilt University US
• SickKids Foundation CA
• Benaroya Research Institute
• University of California, San Francisco US
• Klinikum rechts der Isar DE
• Hospital for Sick Children CA

Related Publications